Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2021-05-25 Board/Management Inform…
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Board/Management Information Classification · 99% confidence The document is explicitly titled "*PRESS RELEASE*" and announces the appointment of a new Chairman of the Supervisory Board, Dr. Gary Phillips, succeeding Laurent Condomine. This type of announcement concerns changes in the company's senior leadership and board structure. This directly aligns with the definition of Board/Management Information (MANG). Although it mentions the 10-K filing in the disclaimer section, the primary content and purpose of this specific document is the management change announcement.
2021-05-25 English
Informations privilégiées / Autres communiqués
Board/Management Information Classification · 98% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces a significant change in senior personnel: the appointment of Dr. Gary Phillips as Chairman of the Supervisory Board, succeeding Laurent Condomine. This directly aligns with the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management. The document is a formal announcement, not a full financial report (like 10-K or IR) or a transcript (CT).
2021-05-25 French
Inside Information / Other news releases
Earnings Release Classification · 99% confidence The document is explicitly titled "# *PRESS RELEASE*" and announces the upcoming presentation of updated clinical trial results (HNSCC and Immunotherapy data) at the 2021 Annual Meeting of the American Society for Clinical Oncology (ASCO). It also mentions an investor event following ASCO. This structure—a formal announcement of clinical data presentation and related corporate events—is characteristic of an Earnings Release (ER) or a general announcement. Since it is a press release detailing key financial/clinical highlights and upcoming events rather than the full financial report (10-K) or a comprehensive interim report (IR), the most appropriate classification is Earnings Release (ER). It is not a Call Transcript (CT), nor is it a simple Report Publication Announcement (RPA) because it contains substantial narrative and data summaries, not just a notification that a report is available. FY 2021
2021-05-22 English
Informations privilégiées / Autres communiqués
Earnings Release Classification · 92% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces new study results for the product NBTXR3 to be presented at the ASCO 2021 congress. It details clinical trial data (Phase I, Phase II/III) for Head and Neck Cancers and Soft Tissue Sarcoma, and mentions an upcoming investor event. This format—a formal announcement of scientific/clinical data and upcoming corporate events, issued by the company—is characteristic of an Earnings Release (ER) or a general announcement. Since it is a detailed announcement of results and future plans rather than just a brief summary of quarterly financials (ER) or a formal regulatory filing like a 10-K, it fits best as a general announcement or a specific type of investor communication. Given the focus on presenting scientific data and clinical trial updates, it strongly aligns with the content often found in an Investor Presentation (IP) or a detailed press release that serves as an update. However, since the text is a press release announcing data presentations and an investor event, and it is not a transcript (CT) or a formal financial report (10-K, IR), the most appropriate general category for a detailed corporate/scientific update that isn't a formal report is often the Investor Presentation (IP) category, as these press releases often precede or summarize the content of an IP. Alternatively, if it were purely a notice of results being published, it would be RPA. Since it contains substantial detail about the results themselves, it leans towards IP or ER. Given the focus on clinical data and strategy updates, IP is a strong candidate, but ER covers initial results announcements. Since it is a press release detailing clinical trial results and future plans, and not a formal quarterly/annual report, it is classified as an Earnings Release (ER) as it announces performance/study outcomes, or potentially an Investor Presentation (IP) due to the depth of scientific detail. Given the structure, it functions as a detailed announcement of scientific progress, which often accompanies or substitutes for an ER in biotech. I will select ER as it announces key performance indicators (study results). FY 2021
2021-05-22 French
Inside Information / Other news releases
Earnings Release Classification · 99% confidence The document is explicitly titled "*PRESS RELEASE*" and announces the upcoming presentation of updated clinical trial results (HNSCC and Immunotherapy data) at the 2021 Annual Meeting of the American Society for Clinical Oncology (ASCO). It also mentions an investor event following ASCO to review the data. This structure—a press release summarizing key data points and announcing future presentations/events—is characteristic of an Earnings Release (ER) or a general announcement. Since the content is focused on clinical trial updates and scientific data presentation rather than comprehensive financial performance for a period, it is not a 10-K or IR. It is also not a Call Transcript (CT) or a formal Investor Presentation (IP). Because it is a press release announcing key operational/clinical updates, the most fitting category is Earnings Release (ER), as these often accompany or precede quarterly financial reporting periods, even if the focus here is clinical data presentation. However, given the strong emphasis on presenting data at a major medical conference (ASCO) and the announcement of a follow-up investor event, it functions primarily as a high-level announcement of scientific progress, which often falls under the broader umbrella of investor communications. Since it is a press release detailing key results and future events, ER is the best fit among the provided options, as it serves as the initial public disclosure of significant operational/clinical milestones, similar to how ERs disclose financial milestones. The document length (14,735 chars) is substantial, ruling out RPA/RNS based on the 'MENU VS MEAL' rule for short announcements. FY 2021
2021-05-19 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 92% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces new results from clinical studies (ASCO 2021 presentations) regarding the product NBTXR3. It details efficacy rates, safety profiles, and future plans, including an upcoming investor event. This format—a formal announcement of scientific/clinical updates and business developments, often released concurrently with major conferences or regulatory filings—is characteristic of an Earnings Release (ER) or a general announcement. Since it is a detailed press release announcing scientific data and future plans rather than just the key financial highlights of a reporting period (like a standard ER), and it is not a transcript (CT), a formal annual report (10-K), or a specific regulatory form, it fits best as an Earnings Release (ER) if it contains financial context, or a general Regulatory Filing (RNS) if it's purely scientific/corporate news. Given the focus on clinical data presentation at a major conference (ASCO) and the announcement of an investor event to discuss these results, it functions as a major corporate update. In many databases, detailed scientific/clinical updates released via press release are often categorized under ER if they are tied to a reporting cycle, or RNS if they are purely informational. Since it is a comprehensive update on product progress and future milestones, and it is not a short announcement pointing to an attached report (ruling out RPA), I will classify it as an Earnings Release (ER) as these often encompass significant operational and clinical milestones for biotech firms, or RNS as a fallback. Given the context of presenting data from a major medical conference (ASCO) and announcing an investor event, ER is a strong candidate, but RNS is the safest general regulatory announcement category if it lacks explicit quarterly financial summaries. However, press releases detailing significant operational/clinical progress are frequently mapped to ER in financial databases. I will lean towards ER as it is a major corporate communication event, but RNS is also plausible. Since it is a press release announcing scientific data and an investor event, and not a formal financial statement, RNS (Regulatory Filings/General Announcement) is the most appropriate general category for non-standard, yet important, corporate news that doesn't fit the specific financial report codes.
2021-05-19 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.